Atlantic Pharma is pleased to announce the launch of NACSYS Acetylcysteine 600mg effervescent tablets.
A new option in the treatment of adult respiratory disorders is now available in the UK.
NACSYS is an effervescent tablet containing 600mg of acetylcysteine and is indicated for use as a mucolytic in respiratory disorders such as bronchitis, emphysema, mucoviscidoses and bronchiectasis in adults.1
With a dose of one tablet dissolved in water once a day, NACSYS provides a very simple and convenient option for patients. Acetylcysteine is the most commonly used mucolytic globally and is recognised by GOLD (Global Initiative for Chronic Obstructive Lung Disease) as a valuable treatment option.2
Costing the NHS £5.50 for a 30-day supply, NACSYS fully reinforces the ALTURiX principle of reliably supplying high quality products which are priced appropriately and help to make a difference to patients’ lives.3
Using usage patterns of mucolytic products over the last year, NACSYS could help to save the Health Services in England, Scotland, Wales and Northern Ireland up to £8.2 million pounds from prescribing budgets.4
Please use the contact us page for further information regarding this news item.
NACSYS Abridged Prescribing Information can be found here
1. Summary of product characteristics. NACSYS 600 mg effervescent tablets. Available at www.medicines.org.uk
2. GOLD Guidelines 2017. Available at www.goldcopd.org
3. MIMS. Available at www.mims.com
4. Data On File, Atlantic Pharma. Budget Impact Model